- Home
- MIST vs CDXS Comparison
MIST vs CDXS Comparison
Compare MIST & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | CDXS |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.2M | 141.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | MIST | CDXS |
|---|---|---|
| Price | $2.27 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 1.0M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $52,932,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.52 |
| 52 Week High | $3.06 | $6.01 |
Technical Indicators
Market Signals| Indicator | MIST | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 38.58 |
| Support Level | $1.61 | $1.62 |
| Resistance Level | $3.06 | $1.95 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 44.02 | 7.35 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.